Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Kiora Pharmaceuticals, Inc. Common Stock

Kiora Pharmaceuticals is a clinical development-stage company focusing on novel therapeutics for the treatment of orphan retinal diseases with high unmet need. This is self-described.

COM:KIORAPHARMA

Kiora Pharmaceuticals

Last Close

3.45

21/11 21:00

Market Cap

9.93M

Beta: -

Volume Today

2.94K

Avg: -

People Not Available